HOUSTON & CHICAGO–(BUSINESS WIRE)–CTMC, a joint venture between MD Anderson Cancer Center and Resilience, has entered a partnership with Syenex to advance the scalability and efficiency of engineered T cell therapies. Through this collaboration, CTMC will gain access to Syenex’s bioengineering systems, which provide a significant improvement in gene delivery efficiency and engineering timelines. Jason Bock, CEO of CTMC, stated, “Our mission is to accelerate the delivery of transformative cell